{"entity":{"id":"met-overexpression","kind":"biomarker","name":"c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)","aka":["c-Met overexpression","MET overexpression","c-Met high","MET IHC 3+","c-Met protein overexpression","MET SP44","c-Met-high NSCLC"],"tldr":"c-Met overexpression is a stain, not a gene change: strong (3+) membrane staining in at least half of tumour cells. It selects telisotuzumab vedotin, an antibody-drug conjugate, in previously treated non-squamous lung cancer.","summary":"The VENTANA MET (SP44) RxDx Assay scores c-Met protein on tumour cell membranes and cytoplasm; the telisotuzumab vedotin (Emrelis, May 2025) label defines high c-Met overexpression as 50 percent or more of tumour cells with strong (3+) staining, as determined by an FDA-approved test, in locally advanced or metastatic non-squamous NSCLC after prior systemic therapy (LUMINOSITY). About a quarter of non-squamous, EGFR wild-type lung cancers meet the bar. Overexpression can occur without amplification or exon 14 skipping and the three readouts are scored separately.","asOf":"2026-09-23","links":[{"label":"EMRELIS prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215"}],"tags":["biomarker","met"],"related":["met-ex14","met-amplification-readout"],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["telisotuzumab-vedotin","telisotuzumab-adizutecan"],"companies":[],"institutions":[],"pathways":[],"terms":["ihc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"met","measurement":"ihc-score","scoringRule":{"text":"50 percent or more of tumour cells showing strong (3+) membranous and/or cytoplasmic c-Met staining on the VENTANA MET (SP44) RxDx Assay.","quote":"MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)","source":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools","sourceLabel":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},"thresholds":[{"value":">= 50% of tumour cells with strong (3+) staining","drugId":"telisotuzumab-vedotin","cancerId":"nsclc","regulator":"FDA","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215","quote":"EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy","status":"current"}],"tests":[],"assays":[],"companionDiagnostics":[{"device":"VENTANA MET (SP44) RxDx Assay","maker":"Ventana Medical Systems (Roche Tissue Diagnostics)","drugs":["telisotuzumab-vedotin"],"indication":"Non-Small Cell Lung Cancer (NSCLC) - Tissue","pma":"P240037 (05/14/2025)","source":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools"}],"forPatient":"If the SP44 stain shows strong c-Met in at least half of your non-squamous lung cancer cells, telisotuzumab vedotin is on label after a first treatment has stopped working. This is a protein stain, so a sequencing report that says nothing about MET does not answer the question; ask whether the stain was done."},"route":"/biomarkers/met-overexpression/","neighbours":{"biomarker":[{"id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/"},{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/"}],"term":[{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}]}}